Anti-Influenza Activity of 6BIGOE: Improved Pharmacological Profile After Encapsulation in PLGA Nanoparticles

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(9), С. 4235 - 4235

Опубликована: Апрель 29, 2025

Influenza A virus (IAV) infections continue to threaten public health. Current strategies, such as vaccines and antiviral drugs, are limited due their time-consuming development drug-resistant strains. Therefore, new effective treatments needed. Here, virus-supportive cellular factors promising drug targets, the encapsulation of candidate substances in poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) is intended improve bioavailability. This study investigates potential indirubin derivative 6-bromoindirubin-3′-glycerol-oxime ether (6BIGOE), a glycogen synthase kinase 3 (GSK-3)β inhibitor, for its regulate IAV replication vitro. The effects 6BIGOE-loaded PLGA NPs on cell metabolism were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) lactate dehydrogenase (LDH) assays A549 Calu-3 cells. Viral spread monitored various IAV-infected lines absence presence free via plaque Western blot analysis. 6BIGOE resulted reduced negative side viability while maintaining efficacy. Both encapsulated exhibited activity, potentially through GSK-3β inhibition disruption key signaling pathways required viral replication. data indicate 6BIGOE, particularly after NPs, further investigation an agent treat infections.

Язык: Английский

---

Influenza vaccination in critically ill AF patients: An underused cardioprotective intervention?

International Journal of Cardiology, Год журнала: 2025, Номер 435, С. 133413 - 133413

Опубликована: Май 21, 2025

---